Skip to Content

Iopidine (apraclonidine ophthalmic) Disease Interactions

There are 3 disease interactions with Iopidine (apraclonidine ophthalmic):

Moderate

Ophthalmic Alpha-2 Adrenergics (Includes Iopidine) ↔ Cardiovascular

Moderate Potential Hazard, Low plausibility

Applies to: Cardiovascular Disease, Hypotension, Cerebrovascular Insufficiency

Topically applied alpha-2 adrenergic receptor agonists are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. In the central nervous system, alpha adrenergic stimulation causes an inhibition of sympathetic vasomotor centers, resulting in decreased peripheral resistance and bradycardia. While the commercially available agents in the U.S. (apraclonidine and brimonidine) are hydrophilic and do not readily distribute across the ocular-blood barrier into the CNS, prolonged use may increase the risk of systemic effects. There have been occasional reports of bradycardia, chest heaviness or burning, palpitation, reduced blood pressure, and orthostatic hypotension when apraclonidine 1% was administered once or twice a day for 4 weeks to individuals not undergoing laser surgery. Therapy with ophthalmic alpha-2 adrenergic agents should be administered cautiously in patients with severe, uncontrolled cardiovascular disease, including hypertension, coronary or cerebrovascular insufficiency, recent myocardial infarction, chronic renal failure, Raynaud's disease, thromboangiitis obliterans, and a predisposition for orthostatic hypotension.

References

  1. Sridharrao B, Badrinath SS "Efficacy and safety of apraclonidine in patients undergoing anterior segment laser surgery." Br J Ophthalmol 73 (1989): 884-7
  2. "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc, Irvine, CA.
  3. King MH, Richards DW "Near syncope and chest tightness after administration of apraclonidine before argon laser iridotomy." Am J Ophthalmol 110 (1990): 308-9
  4. Nordlund JR, Pasquale LR, Robin AL, Rudikoff MT, Ordman J, Chen KS, Walt J "The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine." Arch Ophthalmol 113 (1995): 77-83
  5. Coleman AL, Robin AL, Pollack IP, Rudikoff MT, Enger C, Mayer PR "Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine." Arch Ophthalmol 108 (1990): 1264-7
  6. "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.
View all 6 references
Moderate

Ophthalmic Alpha-2 Adrenergics (Includes Iopidine) ↔ Depression

Moderate Potential Hazard, Low plausibility

Applies to: Depression

Topically applied alpha-2 adrenergic receptor agonists are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. Depression has infrequently been associated with the ocular use of these drugs due to their inhibiting effect on the sympathetic nervous system. Depressed patients should be monitored for exacerbation of their condition during therapy with ophthalmic alpha-2 adrenergic agents.

References

  1. "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.
  2. "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc, Irvine, CA.
Moderate

Ophthalmic Alpha-2 Adrenergics (Includes Iopidine) ↔ Renal/Liver

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction, Liver Disease

Topically applied alpha-2 adrenergic receptor agonists are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. There are limited data concerning the pharmacokinetic disposition or the clinical use of these drugs in patients with renal and/or liver disease. Therapy with ophthalmic alpha-2 adrenergic agents should be administered cautiously in patients with significantly impaired renal or hepatic function.

References

  1. "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc, Irvine, CA.
  2. "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.

Iopidine (apraclonidine ophthalmic) drug Interactions

There are 775 drug interactions with Iopidine (apraclonidine ophthalmic)

Iopidine (apraclonidine ophthalmic) alcohol/food Interactions

There is 1 alcohol/food interaction with Iopidine (apraclonidine ophthalmic)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide